Glucos Viaflo Baxter

Glucos Viaflo Baxter is a pharmaceutical product that contains glucose as its active ingredient, supplied as an intravenous solution for injection. The exact concentration or strength is not specified in the available documentation. Marketed in the European Union, this sterile solution is classified as an excipient used primarily in parenteral nutrition formulations to provide a source of carbohydrate energy. It is intended for use under professional medical supervision.

Glucos Viaflo Baxter is employed in clinical settings as part of parenteral nutrition regimens to supply carbohydrate calories.

- Provides an immediate source of glucose for patients unable to receive enteral feeding. - Supports energy metabolism during surgical procedures or critical illness. - Used to maintain blood glucose levels in patients receiving total parenteral nutrition. - Assists in preventing hypoglycemia in neonatal and pediatric intensive care. - Facilitates formulation of customized nutrition admixtures for adult patients. - Can be combined with amino acid and lipid solutions to create balanced total nutrient admixtures. - Provides flexibility in adjusting carbohydrate concentration to meet individual caloric requirements.

Glucos Viaflo Baxter, as an intravenous glucose solution, may be associated with certain adverse reactions that vary in frequency and severity.

Common: - Transient hyperglycemia or elevated blood glucose levels. - Local irritation or pain at the injection site. - Mild electrolyte disturbances, such as low potassium. - Nausea or vomiting in some patients. - Mild headache or dizziness reported occasionally. - Temporary increase in serum triglyceride levels.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reactions, including rash, itching, or anaphylaxis. - Fluid overload or pulmonary edema in patients with compromised cardiac function. - Severe electrolyte imbalance, such as hypernatremia, requiring medical intervention. - Monitoring of blood parameters is recommended during administration.

When using Glucos Viaflo Baxter, healthcare professionals should observe specific precautions to ensure patient safety and optimal therapeutic outcomes.

- Verify patient’s blood glucose level before infusion to avoid excessive hyperglycemia. - Assess renal and hepatic function, as impaired clearance may affect glucose metabolism. - Adjust infusion rate in patients with cardiac failure to prevent fluid overload. - Use aseptic technique to maintain sterility of the intravenous solution. - Monitor electrolytes, especially potassium and sodium, during prolonged administration. - Consider contraindications such as known hypersensitivity to glucose solutions.

Glucos Viaflo Baxter may interact with other intravenous therapies or medications; awareness of potential interactions helps prevent complications.

Avoid: - Co-administration with high‑dose insulin infusions without glucose monitoring, which can cause severe hypoglycemia. - Simultaneous infusion of hypertonic saline solutions that may exacerbate hypernatremia.

Use with caution: - Concurrent use of diuretics, which can alter electrolyte balance during glucose infusion. - Administration alongside catecholamines (e.g., epinephrine) that may increase glucose production and affect glycemic control. - Overlapping infusion with lipid emulsions, requiring careful monitoring of caloric load. - Use with potassium‑sparing agents, as glucose infusion can shift potassium intracellularly.